
Understand LH and FSH alongside low testosterone, including high and normal patterns, possible causes and questions to discuss with your doctor.

LH, short for luteinising hormone, and FSH, short for follicle-stimulating hormone, are pituitary hormones that help coordinate testicular function. LH stimulates the Leydig cells in the testes to produce testosterone. FSH helps support sperm production.
These hormones belong to the signaling system connecting the brain and testes. A peer-reviewed fertility review describes their different roles within that system. Reading them alongside testosterone helps clinicians assess both the hormonal signal and the testicular response.
This article is for informational purposes only and is not medical advice. Personal interpretation of hormone results and decisions about further testing belong with a qualified clinician.
LH and FSH results may be described as high, low or within the reference range. For a low-testosterone evaluation, the important biological question is whether those signals fit the testosterone result. A normal-range signal is not always an adequate signal for the circumstances.
The European Association of Urology (EAU) guideline uses LH and FSH to help distinguish types of hypogonadism. These patterns guide further investigation. They do not establish a diagnosis or identify its cause by themselves.
When testosterone is confirmed low, high LH can suggest primary hypogonadism. This means the testes may not be responding adequately to hormonal stimulation. FSH is often high as well.
The biological distinction is between the signal and the response: the pituitary is providing stimulation, but testosterone production remains low. This pattern is also called hypergonadotropic hypogonadism.
LH and FSH still have different roles within that pattern. LH relates directly to stimulation of testosterone-producing cells. FSH adds information about the hormonal system supporting sperm production. Reading both results does not mean treating them as interchangeable measurements.
Low LH and FSH alongside low testosterone can suggest secondary hypogonadism. In this pattern, stimulation from the hypothalamus or pituitary is inadequate.
The phrase “inappropriately normal” describes an important variation. LH and FSH may sit within their reference ranges while still being lower than expected in the presence of low testosterone. The normal label describes where the measurement falls, not whether the response suits the body's circumstances.
This is why an unflagged LH result should not automatically end the discussion. The relevant question is whether the measured stimulation makes sense alongside the testosterone finding. That relationship helps determine which possible causes deserve attention next.
Normal testosterone with high LH is a different pattern from confirmed testosterone deficiency. The EAU describes it as compensated or subclinical hypogonadism and says its clinical significance remains unclear.
The distinction matters when reading a report with an abnormal LH flag. A high signal with normal testosterone should not be grouped together with a high signal and low testosterone. Those combinations describe different relationships between stimulation and hormone production.
Before using these patterns to classify testosterone deficiency, the testosterone finding needs clinical confirmation. The EAU bases a late-onset hypogonadism diagnosis on compatible symptoms or signs together with low morning testosterone on at least two occasions. Testing should use a reliable assay under fasting conditions.
The sequence is therefore important: establish the testosterone finding, then use the related hormones to help interpret its origin. Understanding the circumstances surrounding an initial low result provides a useful foundation for that discussion.
The reference-range flag and the clinical assessment answer different questions. One describes a measurement. The other brings that measurement together with symptoms and the rest of the hormone pattern.
In adult men, the clinical question is whether there are symptoms or signs compatible with testosterone deficiency. It is not simply whether LH or FSH appears outside its reference range.
The EAU notes that symptoms are not specific to hypogonadism. Their meaning depends on the broader clinical and biochemical picture. A symptom report therefore needs assessment in its own right rather than being assigned to whichever hormone is flagged.
LH and FSH add a different kind of information: they help clinicians assess the possible origin of a confirmed low-testosterone pattern. The symptom assessment addresses what the person is experiencing. The hormone assessment examines how the signaling system and testes appear to be functioning.
This distinction supports placing symptoms in their wider health context. A useful consultation connects the reported concerns with the laboratory findings instead of allowing either to replace the other.
Fertility concerns also belong in the conversation because FSH participates in sperm production. However, LH and FSH do not answer every fertility question. Their role in that discussion is related to testicular function but is not identical to explaining symptoms of testosterone deficiency.
The EAU lists both testicular causes and causes affecting hypothalamic-pituitary signaling. This is why the medical history matters after the hormone relationship has been identified. The next investigation depends on the pattern and the surrounding circumstances.
Examples of testicular causes listed by the EAU include:
These causes belong to the primary hypogonadism side of the assessment. A clinician considers whether the history supports impaired testicular function rather than selecting a cause from the LH result alone.
The practical value of the classification is that it directs attention toward relevant history and further evaluation. It is a way of organizing the clinical questions, not a substitute for answering them.
The EAU also lists causes involving inadequate stimulation from the hypothalamus or pituitary:
These possibilities help explain why a secondary pattern leads to a different clinical discussion. A review of medications and health conditions may be relevant alongside assessment of the other hormone findings.
The term “secondary” describes the signaling pattern. It does not identify which of these possible causes is responsible. The history and any additional investigations provide that next layer of information.
Acute illness is associated with functional hypogonadism. The EAU advises avoiding testosterone measurement during acute illness. It also recommends morning testing under fasting conditions.
These points concern the testosterone measurement on which the wider interpretation depends. An LH or FSH result does not remove the need to consider whether the accompanying testosterone measurement was obtained under appropriate conditions.
In a clinical review, timing and illness therefore belong beside the hormone values. They help establish whether the available results are suitable for the diagnostic question being asked.
Once testosterone is found to be pathologically low, the EAU recommends measuring LH together with prolactin to help identify the underlying condition. It also states that LH and FSH can support the distinction between primary and secondary hypogonadism.
For secondary hypogonadism, the guideline recommends considering pituitary MRI when:
The EAU gives a weaker recommendation for MRI in severe secondary hypogonadism with total testosterone below 6 nmol/L. That figure concerns imaging in a specific clinical setting. It is not an LH or FSH reference limit.
These considerations form part of a clinician-led assessment of low testosterone. The purpose is to choose investigations that fit the findings rather than assume every low result requires the same set of tests.
Testosterone therapy can suppress the hypothalamic-pituitary-testicular axis and impair fertility, according to the EAU. That makes treatment history and fertility plans relevant to the discussion of hormone results.
The guideline also notes that treatment implications differ by cause. Classifying the pattern therefore has a purpose beyond naming it: the distinction can affect the later clinical conversation. It does not supply a personal treatment plan or settle fertility decisions.
Ask your physician: “Has my low testosterone been confirmed under appropriate conditions? Do LH and FSH suggest a testicular or signaling pattern? Which possible causes and further tests fit my history? How do my fertility plans affect the discussion?”
A normal LH or FSH label can distract from questions about symptoms and possible causes; Testostra addresses that confusion by explaining hormone results in clinical context. Its evidence-led coverage connects low testosterone concerns with related biomarkers and keeps general education separate from individual diagnosis so readers have a clearer basis for conversations with their physician.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra